|
AU1331892A
(en)
|
1991-02-01 |
1992-09-07 |
Coulter Corporation |
Method of producing f(ab')2 fragments of immunoglobulins
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
BRPI9707379B8
(pt)
|
1996-02-09 |
2015-07-07 |
Abbvie Biotechnology Ltd |
Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
|
|
DE69907439T3
(de)
|
1998-05-06 |
2014-01-02 |
Genentech, Inc. |
Reinigung von proteinen durch ionenaustauschchromatographie
|
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
CA2493067A1
(en)
|
2002-07-19 |
2004-01-29 |
Abbott Biotechnology Ltd. |
Treatment of tnf.alpha. related disorders
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US8227241B2
(en)
|
2004-03-12 |
2012-07-24 |
Unigene Laboratories, Inc. |
Bacterial host cell for the direct expression of peptides
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
|
AR054233A1
(es)
|
2005-03-08 |
2007-06-13 |
Pharmacia & Upjohn Co Llc |
Composiciones de anticuerpos igg2
|
|
JP5757495B2
(ja)
|
2005-05-16 |
2015-07-29 |
アッヴィ バイオテクノロジー リミテッド |
びらん性多発性関節炎の治療のためのtnf阻害剤の使用
|
|
EP1885847B1
(en)
|
2005-05-26 |
2011-07-06 |
Cytos Biotechnology AG |
Scalable fermentation process
|
|
PL2390267T3
(pl)
|
2005-06-07 |
2013-09-30 |
Esbatech A Novartis Co Llc |
Stabilne i rozpuszczalne przeciwciała hamujące TNF(alfa)
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
AR058140A1
(es)
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
|
JP5198277B2
(ja)
|
2005-11-01 |
2013-05-15 |
アボツト・バイオテクノロジー・リミテツド |
バイオマーカーを用いて強直性脊椎炎を診断するための方法及び組成物
|
|
EP2738179A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US20080118496A1
(en)
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
WO2007120626A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
TWI542374B
(zh)
|
2006-06-30 |
2016-07-21 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
|
JP5437633B2
(ja)
|
2006-09-11 |
2014-03-12 |
株式会社 免疫生物研究所 |
モノクローナル抗体およびその用途
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
MX345141B
(es)
|
2006-09-13 |
2017-01-18 |
Abbvie Inc * |
Mejoras de cultivos celulares.
|
|
EP2500414A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
EP2089428B1
(en)
|
2006-10-27 |
2013-11-20 |
AbbVie Biotechnology Ltd |
Crystalline anti-htnfalpha antibodies
|
|
RU2518340C2
(ru)
|
2007-03-30 |
2014-06-10 |
Эббви Инк |
Элементы рекомбинантного вектора экспрессии (reves) для усиления экспрессии рекомбинантных белков в клетках-хозяевах
|
|
TWI601823B
(zh)
|
2007-04-26 |
2017-10-11 |
Chugai Pharmaceutical Co Ltd |
Cell culture methods using media containing high concentrations of amino acids
|
|
EP2165194A4
(en)
|
2007-05-31 |
2010-09-08 |
Abbott Lab |
BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
UA107557C2
(xx)
*
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
MX2010001488A
(es)
|
2007-08-08 |
2010-03-01 |
Abbott Lab |
Composiciones y metodos para cristalizar anticuerpos.
|
|
US8383114B2
(en)
|
2007-09-27 |
2013-02-26 |
Amgen Inc. |
Pharmaceutical formulations
|
|
CN101969971A
(zh)
|
2007-11-30 |
2011-02-09 |
雅培制药有限公司 |
蛋白制剂及其制备方法
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
WO2009073805A2
(en)
*
|
2007-12-04 |
2009-06-11 |
Verdezyne, Inc. |
Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
|
|
EP2081025B1
(en)
|
2008-01-15 |
2010-03-10 |
Universiteit Utrecht Holding B.V. |
Method for determining the amino acid sequence of peptides
|
|
NZ586576A
(en)
|
2008-01-15 |
2012-08-31 |
Abbott Lab |
Improved mammalian expression vectors and uses thereof
|
|
RU2537139C2
(ru)
|
2008-01-15 |
2014-12-27 |
Эбботт Гмбх Унд Ко.Кг |
Порошковые белковые композиции и способы их получения
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
|
EP2271671A2
(en)
|
2008-03-24 |
2011-01-12 |
Abbott Biotechnology Ltd. |
Tnf-alpha inhibitors for treating bone loss
|
|
EP2282773B2
(en)
|
2008-05-02 |
2025-03-05 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
CN104974251A
(zh)
|
2008-10-20 |
2015-10-14 |
Abbvie公司 |
在抗体纯化过程中的病毒灭活
|
|
TWI610936B
(zh)
|
2008-10-20 |
2018-01-11 |
艾伯維有限公司 |
使用蛋白質a親和性層析進行抗體之分離及純化
|
|
NZ603619A
(en)
|
2008-10-20 |
2014-05-30 |
Abbvie Inc |
Antibodies that bind to il-12 and methods of purifying the same
|
|
US9393304B2
(en)
|
2008-10-29 |
2016-07-19 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
|
WO2010062896A1
(en)
|
2008-11-28 |
2010-06-03 |
Abbott Laboratories |
Stable antibody compositions and methods for stabilizing same
|
|
CN102348979A
(zh)
|
2009-03-09 |
2012-02-08 |
乔治亚大学研究基金公司 |
胃癌诊断用蛋白标记的鉴定
|
|
CN104490767A
(zh)
|
2009-05-04 |
2015-04-08 |
艾伯维生物技术有限公司 |
人抗TNF-α抗体的稳定高蛋白质浓度制剂
|
|
JP5744856B2
(ja)
|
2009-06-02 |
2015-07-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
フコシル化欠損細胞
|
|
WO2010141855A1
(en)
|
2009-06-05 |
2010-12-09 |
Momenta Pharmaceuticals, Inc. |
Methods of modulating fucosylation of glycoproteins
|
|
WO2011028962A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody coformulations
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
EP3216462A3
(en)
|
2010-02-26 |
2017-12-20 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
|
MX354845B
(es)
|
2010-05-18 |
2018-03-22 |
Abbvie Inc Star |
Aparato y proceso de purificación de proteínas.
|
|
EP3299380B1
(en)
|
2010-05-25 |
2024-08-28 |
F. Hoffmann-La Roche AG |
Methods of purifying polypeptides
|
|
PL2575884T3
(pl)
|
2010-06-03 |
2018-12-31 |
Abbvie Biotechnology Ltd |
Zastosowania i kompozycje do leczenia ropni mnogich pach (HS)
|
|
AU2011305754B2
(en)
|
2010-09-20 |
2015-11-05 |
Abbvie Inc. |
Purification of antibodies using simulated moving bed chromatography
|
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
SG10201508401TA
(en)
|
2010-10-11 |
2015-11-27 |
Abbvie Bahamas Ltd |
Processes for purification of proteins
|
|
US8821865B2
(en)
|
2010-11-11 |
2014-09-02 |
Abbvie Biotechnology Ltd. |
High concentration anti-TNFα antibody liquid formulations
|
|
MX345399B
(es)
|
2010-12-28 |
2017-01-30 |
Chugai Pharmaceutical Co Ltd |
Metodo de cultivo de celulas animales.
|
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
CN103501825B
(zh)
|
2011-05-02 |
2017-03-15 |
免疫医疗公司 |
用于小体积施用的同种异型选择的抗体的超滤浓缩
|
|
LT2837680T
(lt)
|
2011-07-01 |
2020-07-10 |
Amgen Inc. |
Žinduolių ląstelių kultūra
|
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
|
AU2012318590B2
(en)
|
2011-10-04 |
2017-05-18 |
Expression Pathology, Inc. |
SRM/MRM assay for the ephrin type-A receptor 2 protein
|
|
UY34409A
(es)
|
2011-10-24 |
2013-05-31 |
Abbvie Inc |
Inmunoenlazadores dirigidos contra el tnf
|
|
US20140288278A1
(en)
|
2011-10-31 |
2014-09-25 |
Joseph Nti-Gyabaah |
Chromatography process for resolving heterogeneous antibody aggregates
|
|
WO2013114164A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr. Reddy's Laboratories Limited |
Method for obtaining glycoprotein composition with increased afucosylation content
|
|
WO2013114165A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr Reddy's Laboratories Limited |
Process of obtaining glycoprotein composition with increased afucosylation content
|
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
US20150150982A1
(en)
|
2012-06-12 |
2015-06-04 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical formulation for a therapeutic antibody
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
WO2014039903A2
(en)
|
2012-09-07 |
2014-03-13 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of adalimumab
|
|
JP5874587B2
(ja)
|
2012-09-10 |
2016-03-02 |
株式会社島津製作所 |
アミノ酸配列解析方法及び装置
|
|
NO2760138T3
(cg-RX-API-DMAC7.html)
|
2012-10-01 |
2018-08-04 |
|
|
|
CN104822826B
(zh)
|
2012-10-15 |
2019-04-30 |
百时美施贵宝公司 |
用于蛋白产生的哺乳动物细胞培养过程
|
|
EP2934587A4
(en)
|
2012-12-18 |
2016-08-03 |
Merck Sharp & Dohme |
Liquid formulations for an anti-TNF-alpha-antibody
|
|
US9452138B2
(en)
|
2012-12-28 |
2016-09-27 |
Abbott Cardiovascular Systems Inc. |
Delivery of biologic therapeutics
|
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
|
US20140271633A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Mammalian cell culture performance through surfactant supplementation of feed media
|
|
CA2926301A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
JP6465794B2
(ja)
|
2013-04-25 |
2019-02-06 |
株式会社カネカ |
Fab型抗体の分泌量を増大できるFd鎖遺伝子又はL鎖遺伝子
|
|
US9416181B2
(en)
|
2013-05-06 |
2016-08-16 |
Abbvie Inc. |
Compositions for cell culture and methods of using the same
|
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
|
EP3114476A4
(en)
|
2013-10-03 |
2017-11-01 |
Bioanalytix, Inc. |
Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic
|
|
US10376582B2
(en)
|
2013-10-16 |
2019-08-13 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
WO2015140700A1
(en)
|
2014-03-19 |
2015-09-24 |
Dr. Reddy's Laboratories Limited |
Cell culture process
|
|
ES2600488T3
(es)
|
2014-05-23 |
2017-02-09 |
Ares Trading S.A. |
Composición farmacéutica líquida
|
|
HUP1400510A1
(hu)
*
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
|
CN105044222B
(zh)
|
2014-12-19 |
2017-09-12 |
浙江辉肽生命健康科技有限公司 |
生物活性多肽的分析测试和鉴定方法
|
|
US10696735B2
(en)
|
2015-01-21 |
2020-06-30 |
Outlook Therapeutics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
|
TW201636047A
(zh)
*
|
2015-01-28 |
2016-10-16 |
麥博賽恩斯有限公司 |
抗-TNF-α抗體之醫藥調配物
|
|
CN105779394B
(zh)
|
2015-03-20 |
2020-03-24 |
广东东阳光药业有限公司 |
一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法
|
|
MX2018008447A
(es)
|
2016-01-06 |
2019-05-30 |
Oncobiologics Inc |
Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
|
|
CN109153717A
(zh)
|
2016-01-06 |
2019-01-04 |
安口生物公司 |
减少单克隆抗体组合物中的高分子量物类、酸性电荷物类和片段
|
|
MX2018009341A
(es)
|
2016-02-03 |
2019-05-15 |
Oncobiologics Inc |
Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
|
|
MX2018009339A
(es)
|
2016-02-04 |
2019-01-10 |
Oncobiologics Inc |
Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas.
|